Joint position on vitamin D prescription in the adult Mexican population by AMMOM, AMEC, AMG, CMIM, CMO, CMR, CONAMEGER, FEMECOG, and FEMECOT
- PMID: 40512300
- PMCID: PMC12165969
- DOI: 10.1007/s11657-025-01563-y
Joint position on vitamin D prescription in the adult Mexican population by AMMOM, AMEC, AMG, CMIM, CMO, CMR, CONAMEGER, FEMECOG, and FEMECOT
Abstract
Background: Vitamin D deficiency remains a critical health concern linked to skeletal disorders such as osteoporosis, osteomalacia, and fractures. Recent evidence highlights the broader role of vitamin D in preventing chronic conditions, including autoimmune diseases, diabetes, and cardiovascular events. However, inconsistencies in clinical practice across Mexico and limited population-specific data necessitate standardized guidelines to address diagnostic and therapeutic challenges.
Objective: To establish evidence-based recommendations for diagnosing and prescribing vitamin D supplements tailored to the Mexican adult population, reducing practice variability while promoting optimal health outcomes.
Methods: A multidisciplinary panel comprising specialists from nine leading Mexican medical organizations conducted a consensus process using the Delphi methodology. The recommendations were developed using a combined approach, integrating extensive literature reviews with expert consensus to address areas where empirical evidence is limited. The process informed guidelines for vitamin D supplementation, measurement criteria, and therapeutic monitoring.
Results: Key recommendations include: Measuring 25(OH)D levels in adults with risk factors or conditions associated with hypovitaminosis D, avoiding routine screening in healthy individuals. Defining vitamin D deficiency as < 20 ng/mL, insufficiency as 20-29 ng/mL, and sufficiency as 30-100 ng/mL. Preferring cholecalciferol for supplementation, with calcifediol reserved for specific cases requiring rapid correction or compromised hepatic hydroxylation. Regularly monitor serum 25(OH)D concentrations to achieve and maintain levels between 30 and 60 ng/mL, ensuring safety and therapeutic efficacy.
Conclusion: This joint position provides a comprehensive framework for managing hypovitaminosis D in Mexican adults. The recommendations aim to harmonize clinical practices, improve patient outcomes, and inform public health strategies for equitable resource allocation. Ongoing evaluation and stakeholder feedback will ensure adaptability and relevance as new evidence emerges.
Keywords: 25(OH)D; Hypovitaminosis; Supplementation; Vitamin D.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflicts of interest: FTN has nothing to declare in the context of this paper but several ad hoc consultancies/speaking honoraria and/or research funding from AMGEN, Asofarma, FAES Farma, and Menarini. HGH has nothing to declare in the context of this paper but several ad hoc speaking honoraria from AMGEN, Asofarma, and MSD. PAG, RLC, HAA, RBT, ABA, JMC, RMD, EPF, ARE, and AVA have no conflicts of interest. Disclaimer: Although most clinical recommendations are intended to be applied nationwide, social disparities may prevent full implementation in certain regions. However, these recommendations can serve as a valuable reference for public health agencies and policymakers, guiding the improved allocation of health resources based on a solid national medical position. Furthermore, feedback from clinicians and healthcare administrators may lead to future revisions and updates as necessary. Endorsements: The following societies endorse this consensus report: College of Internal Medicine of Mexico (CMIM), Mexican Academy of Geriatrics (AMG), Mexican Association for the Study of Climacteric (AMEC), Mexican Association of Bone and Mineral Metabolism (AMMOM), Mexican College of Orthopedics and Traumatology (CMO), Mexican College of Rheumatology (CMR), National College of Geriatric Medicine (CONAMEGER), Mexican Federation of Obstetrics and Gynecology Colleges (FEMECOG), Mexican Federation of Orthopedics and Traumatology Colleges (FEMECOT).
Similar articles
-
Cholecalciferol or Calcifediol in the Management of Vitamin D Deficiency.Nutrients. 2020 May 31;12(6):1617. doi: 10.3390/nu12061617. Nutrients. 2020. PMID: 32486496 Free PMC article. Review.
-
A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.J Assoc Physicians India. 2023 Jan;71(1):1. J Assoc Physicians India. 2023. PMID: 37116030 Clinical Trial.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults.Nutrients. 2018 Apr 27;10(5):546. doi: 10.3390/nu10050546. Nutrients. 2018. PMID: 29702603 Free PMC article. Review.
-
Clinical Practice in the Prevention, Diagnosis and Treatment of Vitamin D Deficiency: A Central and Eastern European Expert Consensus Statement.Nutrients. 2022 Apr 2;14(7):1483. doi: 10.3390/nu14071483. Nutrients. 2022. PMID: 35406098 Free PMC article. Review.
References
-
- Armas LA, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89(11):5387–5391 - PubMed
-
- Autier P, Gandini S, Mullie P (2012) A systematic review: influence of vitamin d supplementation on serum 25-hydroxyvitamin d concentration. J Clin Endocrinol Metab 97(8):2606–2613 - PubMed
-
- Barker W (2014) Assessment and prevention of falls in older people. Nurs Older People 26(6) - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical